Filter News
Area of Research
News Topics
- (-) Biomedical (2)
- (-) Grid (1)
- (-) Nuclear Energy (2)
- (-) Security (1)
- 3-D Printing/Advanced Manufacturing (4)
- Advanced Reactors (1)
- Artificial Intelligence (3)
- Bioenergy (3)
- Biology (3)
- Buildings (1)
- Chemical Sciences (9)
- Composites (1)
- Computer Science (2)
- Coronavirus (1)
- Critical Materials (1)
- Cybersecurity (1)
- Decarbonization (1)
- Energy Storage (11)
- Environment (2)
- Exascale Computing (1)
- Frontier (1)
- Fusion (1)
- High-Performance Computing (2)
- Isotopes (2)
- Machine Learning (1)
- Materials (12)
- Materials Science (5)
- Microscopy (3)
- Nanotechnology (5)
- National Security (2)
- Neutron Science (5)
- Partnerships (4)
- Physics (6)
- Polymers (2)
- Quantum Science (1)
- Sustainable Energy (1)
- Transformational Challenge Reactor (1)
- Transportation (2)
Media Contacts
Marc-Antoni Racing has licensed a collection of patented energy storage technologies developed at ORNL. The technologies focus on components that enable fast-charging, energy-dense batteries for electric and hybrid vehicles and grid storage.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.
The United Kingdom’s National Nuclear Laboratory and the U.S. Department of Energy’s Oak Ridge National Laboratory have agreed to cooperate on a wide range of nuclear energy research and development efforts that leverage both organizations’ unique expertise and capabilities.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.